Company Overview and News

CB says processing investment proposal by ETI directors

Neither confirming nor denying the speculations that UK-based Lyca Group is nearing a deal to purchase the ETI Group’s assets, Central Bank Governor Dr. Indrajit Coomaraswamy told Mirror Business that the Central Bank is still processing an investment proposal submitted by the ETI directors.  

CB announces 6-month programme to revive ETI Group finance firms

The Central Bank on Tuesday revealed a host of measures to bring the illiquid, mismanaged, non-banking financial institutions (NBFIs) in the ETI Group back into liquidity within six months, after placing the management of the parent company in the hands of an expert panel. 

CB restricts deposit withdrawals of ETI Finance, Swarnamahal Financial Services

2018-01-02 lankabusinessonline
Jan 02, 2018 (LBO) – Sri Lanka’s Central Bank has restricted the withdrawal of maturing deposits and renewal of such deposits of ETI Finance and Swarnamahal Financial Services for six months.

Sri Lanka’s Swarnamahal Financial Services transferred to default board

2017-01-19 lankabusinessonline
Jan 19, 2017 (LBO) – Sri Lanka’s Swarnamahal Financial Services (SFS) has been transferred to default board with with immediate effect following the Securities and Exchange Commission directive on prohibiting related party transactions, a statement said.

USD100mn capital infusion into ETI Finance approved

2016-01-29 lankabusinessonline
Jan 29, 2016 (LBO) – The Central Bank has approved a proposal to infuse 100 million US dollars into the share capital of ETI Finance, Swarnamahal Financial Services said in a stock exchange filing....

Central Bank approves USD100mn capital infusion into ETI Finance

2016-01-29 lankabusinessonline
Jan 29, 2016 (LBO) – The Central Bank has approved a proposal to infuse 100 million US dollars into the share capital of ETI Finance, Swarnamahal Financial Services said in a stock exchange filing....

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

21h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

21h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...